127 related articles for article (PubMed ID: 2902642)
1. Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients.
Izmeth MG; Khan SY; Kumarajeewa DI; Shivanathan S; Veall RM; Wiley YV
Pharmatherapeutica; 1988; 5(4):217-27. PubMed ID: 2902642
[TBL] [Abstract][Full Text] [Related]
2. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
Walker CA
Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
[TBL] [Abstract][Full Text] [Related]
3. An open clinical trial with the long-acting neuroleptic zuclopenthixol decanoate in the maintenance treatment of schizophrenia.
Kazi HA
Pharmatherapeutica; 1986; 4(9):555-60. PubMed ID: 3763650
[TBL] [Abstract][Full Text] [Related]
4. Zuclopenthixol and melperon in the treatment of elderly patients: a double-blind, controlled, multi-centre study.
Nygaard H; Bakke K; Brudvik E; Lien GK; Moe TJ; Elgen K
Pharmatherapeutica; 1988; 5(3):152-8. PubMed ID: 2896359
[TBL] [Abstract][Full Text] [Related]
5. Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study.
Fuglum E; Schillinger A; Andersen JB; Belstad BE; Jensen D; Müller F; Müller KJ; Schulstad B; Elgen K
Pharmatherapeutica; 1989; 5(5):285-91. PubMed ID: 2568639
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of chronic schizophrenics with clopenthixol decanoate.
Borsetti G; Rocco P; Spilimbergo PG; Giavedoni A; Frangiamone L; Beccaceci A; Judice A; Cisternino M; Volterra V
Pharmatherapeutica; 1984; 4(1):53-6. PubMed ID: 6150492
[TBL] [Abstract][Full Text] [Related]
7. A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders.
Singh I; Owino WJ
J Intellect Disabil Res; 1992 Dec; 36 ( Pt 6)():541-9. PubMed ID: 1477491
[TBL] [Abstract][Full Text] [Related]
8. Clopenthixol decanoate in the treatment of chronic schizophrenic in-patients.
Viswanathan R; Rajhkowa S
Pharmatherapeutica; 1982; 3(2):93-9. PubMed ID: 7100227
[TBL] [Abstract][Full Text] [Related]
9. A clinical assessment of zuclopenthixol dihydrochloride (Clopixol tablets) in the treatment of psychotic illness.
Mann BS; Moslehuddin KS; Owen RT; Clayton AR; Rohatgi KK; Sud P; Vaddadi KS
Pharmatherapeutica; 1985; 4(6):387-92. PubMed ID: 2867559
[TBL] [Abstract][Full Text] [Related]
10. Clopenthixol decanoate in the management of aggressive mentally handicapped patients.
Mlele TJ; Wiley YV
Br J Psychiatry; 1986 Sep; 149():373-6. PubMed ID: 3779305
[No Abstract] [Full Text] [Related]
11. Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state.
Jørgensen A; Aaes-Jørgensen T; Gravem A; Amthor KF; Dencker SJ; Rosell I; Baastrup PC; Buckhave J; Gram LF
Psychopharmacology (Berl); 1985; 87(3):364-7. PubMed ID: 2867572
[TBL] [Abstract][Full Text] [Related]
12. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study.
Wistedt B; Koskinen T; Thelander S; Nerdrum T; Pedersen V; Mølbjerg C
Acta Psychiatr Scand; 1991 Jul; 84(1):14-21. PubMed ID: 1681680
[TBL] [Abstract][Full Text] [Related]
13. A 5-year follow-up study of chronic schizophrenics treated with clopenthixol decanoate.
Carney MW
Pharmatherapeutica; 1984; 4(1):57-63. PubMed ID: 6150493
[TBL] [Abstract][Full Text] [Related]
14. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics.
Chin CN; Hamid AR; Philip G; Ramlee T; Mahmud M; Zulkifli G; Loh CC; Zakariah MS; Norhamidah MS; Suraya Y; Roslan KA; Chandramohan P; Cheah YC; Leonard AO
Med J Malaysia; 1998 Dec; 53(4):365-71. PubMed ID: 10971979
[TBL] [Abstract][Full Text] [Related]
15. [A new injectable delayed-action neuroleptic with sedative and antipsychotic action: cis-(Z)-clopenthixol decanoate. Clinical trials].
Lambert PA; Chabannes JP
Encephale; 1984; 10(2):83-91. PubMed ID: 6381033
[TBL] [Abstract][Full Text] [Related]
16. A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - secondary parameter analyses.
Hässler F; Glaser T; Pap AF; Beneke M; Diefenbacher A; Reis O;
Pharmacopsychiatry; 2008 Nov; 41(6):232-9. PubMed ID: 19067260
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo.
Balant LP; Balant-Gorgia AE; Eisele R; Reith B; Gex-Fabry M; Garrone G
Pharmacopsychiatry; 1989 Nov; 22(6):250-4. PubMed ID: 2575763
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
[TBL] [Abstract][Full Text] [Related]
19. Acute functional psychoses: treatment with zuclopenthixol dihydrochloride ('Clopixol') tablets.
Bhattacharyya SN; Ghoshal J; Sharma SK; Halstead N; John B; Launer MA; Mukherjee PK; Zigmond AS
Pharmatherapeutica; 1987; 5(1):1-8. PubMed ID: 3602019
[TBL] [Abstract][Full Text] [Related]
20. Zuclopenthixol acetate (5% in 'Viscoleo'): single-dose treatment for acutely disturbed psychotic patients.
Chakravarti SK; Muthu A; Muthu PK; Naik P; Pinto RT
Curr Med Res Opin; 1990; 12(1):58-65. PubMed ID: 1971560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
